Trust Company’s Sarepta Therapeutics SRPT Stock Holding History

Trust Company’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10	Closed	-$1.25K	–	424
2024 Q3	$1.25K	Buy	+10	New	+$1.38K	﹤0.01%	378

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Trust Company's SRPT Position: Q4 2024 in Review

Trust Company sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 10 shares — an estimated $1.25K sold.

Trust Company first reported a position in SRPT in Q3 2024 and held it in 1 quarter. The position peaked at $1.25K in Q3 2024. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

Trust Company reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
Trust Company sold 10 Sarepta Therapeutics shares in Q4 2024, an estimated $1.25K.
Trust Company first reported a position in Sarepta Therapeutics in Q3 2024 and held it in 1 quarter.
Trust Company's Sarepta Therapeutics position peaked at $1.25K in Q3 2024.
464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Trust Company's 13F filing for Q4 2024, filed 14 Jan 2025.